Huang Erica, Huynh Linda My, Tran Joshua, Gordon Adam M, Chandhoke Ryan, Morales Blanca, Skarecky Douglas, Ahlering Thomas E
Department of Urology, University of California, Orange, CA 92868, USA.
MD-PhD Scholars Program, University of Nebraska Medical Center, Omaha, NE 69198, USA.
Cancers (Basel). 2022 Aug 23;14(17):4078. doi: 10.3390/cancers14174078.
Biochemical recurrence (BCR) following radical prostatectomy (RP) is an unreliable predictor of prostate cancer (PC) progression. This study was a retrospective cohort analysis of prospectively collected data (407/1895) of men with BCR at a tertiary referral center. Patients were assessed for active observation (AO) compared with a treatment group (TG) utilizing doubling time (DT) kinetics. Risk assessment was based on the initial DT (>12 vs. <12 months), then based on the DT pattern (changed over time). Those with unstable, rapidly decreasing DTs received treatment. Those with increasing and slowly decreasing DTs prompted observation. The primary outcome was PC mortality, safety, and efficacy of observations based on DT kinetics. The secondary outcome was BCR patients managed with or without treatment. The median follow-up was 7.5 years (IQR 3.9−10.7). The PCSM in TG and AO was 10.7% and 0%, respectively (p < 0.001). The initial DT was >12 months in 73.6% of AO versus 22.6% of TG (p < 0.001). An increasing DT pattern was observed in 71.5% of AO versus 32.7% of TG (p < 0.001). Utilizing the Cleveland Clinic’s PCSM nomogram, at 10 years, predicted and observed PCSM was 8.6% and 9.5% (p = 0.78), respectively. In conclusion, one-third of patients with BCR post-RP were managed without treatment using DT kinetics, avoiding treatment-related complications, quality-of-life issues, and expenses.
根治性前列腺切除术后的生化复发(BCR)是前列腺癌(PC)进展的不可靠预测指标。本研究是对一家三级转诊中心前瞻性收集的407例/1895例BCR男性患者数据进行的回顾性队列分析。与采用倍增时间(DT)动力学的治疗组(TG)相比,对患者进行了主动观察(AO)评估。风险评估基于初始DT(>12个月与<12个月),然后基于DT模式(随时间变化)。DT不稳定、快速下降的患者接受治疗。DT上升和缓慢下降的患者则进行观察。主要结局是基于DT动力学的PC死亡率、观察的安全性和有效性。次要结局是接受或未接受治疗的BCR患者。中位随访时间为7.5年(四分位间距3.9 - 10.7年)。TG组和AO组的前列腺癌特异性死亡率(PCSM)分别为10.7%和0%(p<0.001)。AO组73.6%的患者初始DT>12个月,而TG组为22.6%(p<0.001)。AO组71.5%的患者观察到DT呈上升模式,而TG组为32.7%(p<0.001)。使用克利夫兰诊所的PCSM列线图,在10年时,预测的和观察到的PCSM分别为8.6%和9.5%(p = 0.78)。总之,三分之一的RP术后BCR患者使用DT动力学未接受治疗,避免了与治疗相关的并发症、生活质量问题和费用。